Marisa Wexler, MS,  senior science writer—

An anti-inflammatory molecule, known as the complement inhibitor zilucoplan, was seen to significantly ease disease severity in generalized myasthenia gravis (gMG) patients at its higher dose and to have a favorable safety profile, data from a Phase 2 clinical trial show. These results informed the dose chosen — 0.3 mg/kg…

Myasthenia gravis (MG) can occur in very elderly patients, a recent case report highlights. As such, there is a need for early diagnosis in this population, which can allow for better clinical outcomes. A case report with that finding, “Very late onset of myasthenia gravis: case report…

People with myasthenia gravis (MG) are at higher risk of developing serious infections than those without the condition, a recent study has found. Although more research into the causes is needed, this finding may have implications for prevention strategies such as vaccinations and preventive antibiotic use, the researchers said.

The anticholinergic agent glycopyrrolate — known to decrease stomach acid and saliva production — could be safely used to control “death rattle” breathing in people with myasthenia gravis (MG), a recent case report suggests. The report, titled “Glycopyrrolate and the Management of “Death Rattle” in…

Administration of the probiotic bifidobacteria may ease myasthenia gravis (MG) symptoms by regulating the behavior of immune cells and altering the makeup of gut bacteria, a study in rats suggests. The study, “Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats,”…

Variations in the gene DRB1 are associated with different risks of developing late-onset myasthenia gravis (LOMG), a recent meta-analysis suggests. This finding may lead to the identification of promising biomarkers for LOMG risk, the researchers said. The analysis, titled “The associations of HLA-DRB1 gene polymorphisms…

A recent meta-analysis has identified factors that put patients with myasthenia gravis at risk for complications following surgery to remove their thymus. These factors include having generalized myasthenia gravis (as opposed to the ocular form), symptoms in the head and neck, and tumors on the thymus. The analysis…

A type of immune cells called natural killer (NK) cells may be able to reduce symptoms of myasthenia gravis (MG) by regulating other components of the immune system, a study in rats showed. Targeting these cells might be a valid therapeutic pathway for treatment of MG and other…

The majority of myasthenia gravis (MG) acute exacerbations are associated with infections or with certain medications, a recent study suggests. These findings suggest that patients on certain medications, such as beta blockers and antibiotics, should be closely monitored and highlight the importance of vaccination. The study, titled, “…

For people with thymomas, certain risk factors, such as clusters of developing B-cells, called germinal centers, in their thymuses, may make them more likely to develop myasthenia gravis (MG), a study suggests. Other factors that may contribute to MG development in people with thymomas include higher levels of…